<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03555617</url>
  </required_header>
  <id_info>
    <org_study_id>0174</org_study_id>
    <nct_id>NCT03555617</nct_id>
  </id_info>
  <brief_title>Food-effect, Drug-Drug Interaction (DDI), and Formulation Bridging Study</brief_title>
  <official_title>A Phase 1, Open-Label, 2-Cohort Study to Assess the Single Dose Pharmacokinetics of Two Formulations of TD-1473 and to Assess the Effect of a High-Fat Meal and Itraconazole on the Pharmacokinetics of TD-1473 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Theravance Biopharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Theravance Biopharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, 2-cohort, food-effect, DDI, and formulation bridging study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 13, 2018</start_date>
  <completion_date type="Actual">July 15, 2018</completion_date>
  <primary_completion_date type="Actual">July 15, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed concentration (Cmax) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum observed concentration (tmax) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from hour 0 to the last measurable concentration (AUC0-last) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve extrapolated to infinity (AUC0-inf) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (t1/2) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (Cl/F) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent volume of distribution (Vz/F) in Plasma</measure>
    <time_frame>Up to 8 days post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>TD-1473 formulation bridging &amp; food effect</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive, on Day 1 of each period, a single 100 mg oral dose of the tablet formulation of TD-1473 in the fed or fasted state, or the PIC formulation of TD-1473 in the fasted state, as part of a 3-period, crossover design.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1473 with Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1. In Period 2, subjects will receive, in the fasted state, single oral doses of 200 mg itraconazole solution on Days -4 through 7 for a total of 11 days, with a single 100 mg oral dose of the tablet formulation of TD-1473 co-administered on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TD-1473 without Itraconazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single 100 mg oral dose of the tablet formulation of TD-1473 in the fasted state on Day 1 of Period 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TD-1473</intervention_name>
    <description>oral capsule/tablet, QD</description>
    <arm_group_label>TD-1473 formulation bridging &amp; food effect</arm_group_label>
    <arm_group_label>TD-1473 with Itraconazole</arm_group_label>
    <arm_group_label>TD-1473 without Itraconazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Itraconazole</intervention_name>
    <description>oral solution, QD</description>
    <arm_group_label>TD-1473 with Itraconazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 to 55 years old

          -  Male subjects must abstain from sexual intercourse or use a highly effective method of
             birth control

          -  Women of child bearing potential must have a negative pregnancy test and either
             abstain from sex or use a highly effective method of birth control

          -  Body Mass Index (BMI) 18 to 32 kg/m2

          -  Willing and able to give informed consent

          -  Additional inclusion criteria apply

        Exclusion Criteria:

          -  Planning to conceive a child during the study or within 2 months after the last dose
             of study drug

          -  Is positive for hepatitis A, B or C, and/or HIV

          -  Has clinically significant abnormalities in baseline laboratory evaluations

          -  Subject has a clinically significant abnormal electrocardiogram (ECG)

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days prior to screening or is currently participating in another trial of an
             investigational drug (or medical device)

          -  Additional exclusion criteria apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Theravance Biopharma</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>June 1, 2018</study_first_submitted>
  <study_first_submitted_qc>June 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 13, 2018</study_first_posted>
  <last_update_submitted>January 21, 2020</last_update_submitted>
  <last_update_submitted_qc>January 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>healthy volunteers</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>itraconazole</keyword>
  <keyword>CYP3A</keyword>
  <keyword>P-gp</keyword>
  <keyword>Inflammatory Bowel Disease</keyword>
  <keyword>IBD</keyword>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Itraconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Theravance Biopharma, Inc. will not be sharing individual de-identified participant data or other relevant study documents.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

